Global menu

Our global pages

Close

Eversheds advises Horizon Pharma PLC on European aspects of its $800 million acquisition of Raptor Pharmaceutical

  • Global
  • United Kingdom
  • Netherlands
  • Germany
  • France
  • Sweden
  • Belgium

    19-09-2016

    Eversheds has advised Horizon Pharma plc on the European aspects of its $800 million acquisition of Raptor Pharmaceutical corporation which strengthens Horizon’s focus on rare disease and bolstering their expansion into Europe and other international markets.

    The Eversheds team consisted of teams in UK, Netherlands Germany, France, Sweden, Norway, Denmark and Belgium. It included the corporate M&A team of Robin Johnson assisted by principal associate, Simon Procter and the employment team of Paul Cotton assisted by associates Aida Geragusian and Corrine Bentham. International corporate and employment teams included Miriam Van Ee and Marieke Koster (Netherlands), Christian Mense and Thomas Barth (Germany), Charles Bresson, Jeremy Juanola and Sarah Ayoub (France), Anna-Carin Ljungberg (Sweden), Anne Marie Abrahamson (Lundgrens, Denmark), Kristine Fremstad Moen (Haavind, Norway) and Stephanie Nijs, Bernd De Marrez and Stefan Corbanie (Belgium).

    The acquisition sees the addition of Procysbi, a treatment for nephropathic cystinosis, a rare metabolic disorder, and Quinsair, which is given to cystic fibrosis patients, to Horizon’s rare disease portfolio.

    Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercialising differentiated and accessible medicines that address unmet medical needs. The company markets nine medicines through its orphan, rheumatology and primary care business units. Horizon's global headquarters are in Dublin, Ireland.

    Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on the development and commercialization of transformative therapeutics for rare, debilitating and often fatal diseases.

    The transaction is expected to close in the fourth quarter of 2016.

    Paul Cotton, Partner, said:

    “We are very pleased to have helped on the European aspects of this transaction, helping Horizon advance their international business. We look forward to working with them in the future.”

    Eversheds regularly advises international companies from the pharmaceutical and life sciences industry in all areas of business law.

    Disclaimer

    This information is for guidance purposes only and should not be regarded as a substitute for taking legal advice. Please refer to the full terms and conditions on our website.

    < Go back

    Print Friendly and PDF
    Register to receive regular updates via email.